Research That Matters - Long-Acting Injectable Buprenorphine for Opioid Use Disorder

Account Registration

Already a member?

"*" indicates required fields

Step 1 of 3

Username

Name

Password*

Strength indicator

Recommendations: at least 12 characters in length, include a mix of character types (uppercase, lowercase, numbers, special characters %$^&), do not use common words or phrases

Organization

Occupation Category*

Address

This field is hidden when viewing the form

occupational_category_audience_kdm

This field is hidden when viewing the form

occupational_category_audience_kdm

Research That Matters – Long-Acting Injectable Buprenorphine for Opioid Use Disorder

This six-month observational study of 227 patients with moderate to severe opioid use disorder demonstrated that monthly injectable extended-release buprenorphine significantly improved treatment adherence, reduced opioid use, and lowered healthcare utilization compared to baseline. Patients experienced:

a 60% reduction in opioid use
40% fewer emergency department visits
35% fewer hospitalizations
high satisfaction and improved quality of life.

By eliminating the need for daily dosing, long-acting buprenorphine addressed common adherence challenges and showed strong potential to support sustained recovery while reducing healthcare system burden, reinforcing the value of expanded access and payer coverage for long-acting MOUD options.

Want to Read more?

To view this content, please sign up or log in to your account.
Create an account in seconds or log in if you’re already a member.